Longitudinal Observational Study on Immune Thrombocytopenia

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University People's Hospital

About this trial

Immune Thrombocytopenia (ITP) is a bleeding disorder characterized by immune-mediated destruction and/or impaired production of platelets, leading to clinical manifestations such as petechiae, purpura, mucosal bleeding, and in severe cases, life-threatening visceral or intracranial hemorrhage. Research on the diagnosis, treatment, and prognosis of ITP is critical for improving patient outcomes and quality of life. However, most existing hematologic cohort studies are limited to single-center or small multicenter samples, lacking comprehensive, large-scale prospective investigations.

To address this gap, our center plans to conduct a large-sample, combined retrospective and prospective longitudinal observational cohort study of ITP patients. The study will enroll patients to collect baseline demographic and diagnostic data, followed by longitudinal follow-up via questionnaires, telephone interviews, video consultations, online platforms, and in-person visits. Key variables including treatment regimens, comorbidities, and prognostic outcomes will be systematically recorded. Additionally, hospitalization and outpatient expenditure data will be extracted from electronic medical records.

This study aims to provide high-quality real-world evidence on the epidemiology, treatment patterns, clinical outcomes, and healthcare costs of ITP patients in China, ultimately informing clinical decision-making and health policy.

Eligibility criteria

Qualifiers

Patients with confirmed diagnosis of ITP

Patients treated at Peking University People's Hospital since January 1, 2005

Disqualifiers

Any condition that may render follow-up data unreliable, including but not limited to severe psychiatric disorders"

Patients deemed ineligible for the study by investigators"

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

2,000 Participants
are grouped into 3 trial groups

Sponsors and collaborators

Peking University People's Hospital

Lead sponsor

Jiangsu Provincial People's Hospital

Collaborator

Wuhan TongJi Hospital

Collaborator